Increased cardiac injury in NZB/W F1 mice received antibody against human parvovirus B19 VP1 unique region protein

Molecular Immunology

Volumn 48, Issue 12-13, 2011, Pages 1518-1524

  Tzang, Bor Show ^a,b   Lin, Tsung Ming ^a   Tsai, Chun Chou ^a   Hsu, Jeng Dong ^a,b   Yang, Lien Chuan ^b   Hsu, Tsai Ching ^a,b  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Cardiac injury; Human parvovirus B19 (B19); Systemic lupus erythematosus (SLE); VP1 unique region protein (VP1u)

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CREATINE KINASE MB; FATTY ACID BINDING PROTEIN; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 1BETA; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38; TUMOR NECROSIS FACTOR ALPHA; VIRUS ANTIBODY; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; FEMALE; HEART INJURY; HUMAN PARVOVIRUS B19; LYMPHOCYTIC INFILTRATION; MOUSE; NEW ZEALAND BLACK MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; CAPSID PROTEINS; FEMALE; HEART; HEART DISEASES; HEART VENTRICLES; IMMUNIZATION, PASSIVE; IMMUNOBLOTTING; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOTOXIN-ALPHA; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED NZB; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PARVOVIRUS B19, HUMAN; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

MUS; ORYCTOLAGUS CUNICULUS; PARVOVIRUS;

EID: 79957838855     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2011.04.013     Document Type: Article

References (58)

1. Ainiala H., Hietaharju A., Dastidar P., Loukkola J., Lehtimäki T., Peltola J., Korpela M., Heinonen T., Nikkari S.T. Increased serum matrix metalloproteinase 9 levels in systemic lupus erythematosus patients with neuropsychiatric manifestations and brain magnetic resonance imaging abnormalities. Arthritis Rheum. 2004, 50:858-865.
2. Alter P., Rupp H., Maisch B. Activated nuclear transcription factor kappaB in patients with myocarditis and dilated cardiomyopathy-relation to inflammation and cardiac function. Biochem. Biophys. Res. Commun. 2006, 339:180-187.
3. Amoroso A., Cacciapaglia F., De Castro S., Battagliese A., Coppolino G., Galluzzo S., Vadacca M., Afeltra A. The adjunctive role of antiphospholipid antibodies in systemic lupus erythematosus cardiac involvement. Clin. Exp. Rheumatol. 2006, 24:287-294.
4. Andréoletti L., Lévêque N., Boulagnon C., Brasselet C., Fornes P. Viral causes of human myocarditis. Arch. Cardiovasc. Dis. 2009, 102:559-568.
5. Arakawa N., Nakamura M., Endo H., Sugawara S., Suzuki T., Hiramori K. Brain natriuretic peptide and cardiac rupture after acute myocardial infarction. Intern. Med. 2001, 40:232-236.
6. Aslanidis S., Pyrpasopoulou A., Kontotasios K., Doumas S., Zamboulis C. Parvovirus B19 infection and systemic lupus erythematosus: activation of an aberrant pathway?. Eur. J. Intern. Med. 2008, 19:314-318.
7. Bock C.T., Klingel K., Aberle S., Duechting A., Lupescu A., Lang F., Kandolf R. Human parvovirus B19. A new emerging pathogen of inflammatory cardiomyopathy. J. Vet. Med. B: Infect. Dis. Vet. Public Health 2005, 52:340-343.
8. Bönsch C., Kempf C., Ros C. Interaction of parvovirus B19 with human erythrocytes alters virus structure and cell membrane integrity. J. Virol. 2008, 82:11784-11791.
9. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
10. Canaan S., Zádori Z., Ghomashchi F., Bollinger J., Sadilek M., Moreau M.E., Tijssen P., Gelb M.H. Interfacial enzymology of parvovirus phospholipases A2. J. Biol. Chem. 2004, 279:14502-14508.
11. Chen D.Y., Tzang B.S., Chen Y.M., Lan J.L., Tsai C.C., Hsu T.C. The association of anti-parvovirus B19-VP1 unique region antibodies with antiphospholipid antibodies in patients with antiphospholipid syndrome. Clin. Chim. Acta 2010, 411:1084-1089.
12. Cihakova D., Rose N.R. Pathogenesis of myocarditis and dilated cardiomyopathy. Adv. Immunol. 2008, 99:95-114.
13. Clerk A., Sugden P.H. Inflame my heart (by p38-MAPK). Circ. Res. 2006, 99:455-458.
14. Dorsch S., Liebisch G., Kaufmann B., von Landenberg P., Hoffmann J.H., Drobnik W., Modrow S. The VP1 unique region of parvovirus B19 and its constituent phospholipase A2-like activity. J. Virol. 2002, 76:2014-2018.
15. Faber-Elmann A., Sthoeger Z., Tcherniack A., Dayan M., Mozes E. Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus. Clin. Exp. Immunol. 2002, 127:393-398.
16. Filippone C., Zhi N., Wong S., Lu J., Kajigaya S., Gallinella G., Kakkola L., Söderlund-Venermo M., Young N.S., Brown K.E. VP1u phospholipase activity is critical for infectivity of full-length parvovirus B19 genomic clones. Virology 2008, 374:444-452.
17. Gardner D.G. Natriuretic peptides: markers or modulators of cardiac hypertrophy?. Trends Endocrinol. Metab. 2003, 14:411-416.
18. Goetzl E.J., Banda M.J., Leppert D. Matrix metalloproteinases and immunity. J. Immunol. 1995, 156:1-4.
19. Hsu T.C., Tsay G.J. Human parvovirus B19 infection in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2001, 40:152-157.
20. Hsu T.C., Chen Y.C., Lai W.X., Chiang S.Y., Huang C.Y., Tzang B.S. Beneficial effects of treatment with cystamine on brain in NZB/W F1 mice. Eur. J. Pharmacol. 2008, 591:307-314.
21. Huang C.Y., Hsu T.C., Kuo W.W., Wu S.P., Lin Y.M., Yen C.Y., Wu J.H., Tzang B.S. Beneficial effects of taurine on cardiac abnormality in NZB/W F1 mice fed with a high-cholesterol diet. J. Agric. Food Chem. 2009, 57:8635-8642.
22. Kandolf R., Bültmann B., Klingel K., Bock C.T. Molecular mechanisms and consequences of cardiac viral infections. Pathologe 2008, 29(Suppl. 2):112-117.
23. Kerr J.R., Tyrrell D.A. Cytokines in parvovirus B19 infection as an aid to understanding chronic fatigue syndrome. Curr. Pain Headache Rep. 2003, 7:333-341.
24. Klingel K., Sauter M., Bock C.T., Szalay G., Schnorr J.J., Kandolf R. Molecular pathology of inflammatory cardiomyopathy. Med. Microbiol. Immunol. 2004, 193:101-107.
25. Kühl U., Pauschinger M., Bock T., Klingel K., Schwimmbeck C.P., Seeberg B., Krautwurm L., Poller W., Schultheiss H.P., Kandolf R. Parvovirus B19 infection mimicking acute myocardial infarction. Circulation 2003, 108:945-950.
26. Kühl U., Lassner D., Pauschinger M., Gross U.M., Seeberg B., Noutsias M., Poller W., Schultheiss H.P. Prevalence of erythrovirus genotypes in the myocardium of patients with dilated cardiomyopathy. J. Med. Virol. 2008, 80:1243-1251.
27. Lehmann H.W., Modrow S. Parvovirus B19 infection and autoimmune disease. Autoimmun. Rev. 2003, 2:218-223.
28. Li H., Mittal A., Paul P.K., Kumar M., Srivastava D.S., Tyagi S.C., Kumar A. Tumor necrosis factor-related weak inducer of apoptosis augments matrix metalloproteinase 9 (MMP-9) production in skeletal muscle through the activation of nuclear factor-kappaB-inducing kinase and p38 mitogen-activated protein kinase: a potential role of MMP-9 in myopathy. J. Biol. Chem. 2009, 284:4439-4450.
29. Lindner J., Noutsias M., Lassner D., Wenzel J., Schultheiss H.P., Kuehl U., Modrow S. Adaptive immune responses against parvovirus B19 in patients with myocardial disease. J. Clin. Virol. 2009, 44:27-32.
30. Lu J., Zhi N., Wong S., Brown K.F. Activation of synoviocytes by the secreted phospholipase A2 motif in the VP1-unique region of parvovirus B19 minor capsid protein. J. Infect. Dis. 2006, 193:582-590.
31. Manzi S., Meilahn E.N., Rairie J.E., Conte C.G., Medsger T.A., Jansen-McWilliams L., D'Agostino R.B., Kuller L.H. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am. J. Epidemiol. 1997, 145:408-415.
32. Meyer O. Parvovirus B19 and autoimmune diseases. Joint Bone Spine 2003, 70:6-11.
33. Morris S.A., Helmer D., Pesce M., Giglio J. Clinical utility of CKMB isoform determinations in patients who present to the emergency department with continuous or resolved chest pain. J. Emerg. Med. 2000, 19:21-26.
34. Musiani M., Manaresi E., Gallinella G., Venturoli S., Zuffi E., Zerbini M. Immunoreactivity against linear epitopes of parvovirus B19 structural proteins. Immunodominance of the amino-terminal half of the unique region of VP1. J. Med. Virol. 2000, 60:347-352.
35. Muslin A.J. MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin. Sci. (Lond.) 2008, 115:203-218.
36. Nie X., Zhang G., Xu D., Sun X., Li Z., Li X., Zhang X., He F., Li Y. The VP1-unique region of parvovirus B19 induces myocardial injury in mice. Scand. J. Infect. Dis. 2010, 42:121-128.
37. Nigro G., Bastianon V., Colloridi V., Ventriglia F., Gallo P., D'Amati G., Koch W.C., Adler S.P. Human parvovirus B19 infection in infancy associated with acute and chronic lymphocytic myocarditis and high cytokine levels: report of 3 cases and review. Clin. Infect. Dis. 2000, 31:65-69.
38. Pankuweit S., Moll R., Baandrup U., Portig I., Hufnagel G., Maisch B. Prevalence of the parvovirus B19 genome in endomyocardial biopsy specimens. Hum. Pathol. 2003, 34:497-503.
39. Pavlovic M., Kats A., Cavallo M., Shoenfeld Y. Clinical and molecular evidence for association of SLE with parvovirus B19. Lupus 2010, 19:783-792.
40. Ram M., Sherer Y., Shoenfeld Y. Matrix metalloproteinase-9 and autoimmune diseases. J. Clin. Immunol. 2006, 26:299-307.
41. Sato H., Kita M., Seiki M. v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements. A mechanism regulating gene expression independent of that by inflammatory cytokines. J. Biol. Chem. 1993, 268:23460-23468.
42. Schowengerdt K.O., Ni J., Denfield S.W., Gajarski R.J., Bowles N.E., Rosenthal G., Kearney D.L., Price J.K., Rogers B.B., Schauer G.M., Chinnock R.E., Towbin J.A. Association of parvovirus B19 genome in children with myocarditis and cardiac allograft rejection: diagnosis using the polymerase chain reaction. Circulation 1997, 96:3549-3554.
43. Seishima M., Shibuya Y., Watanabe K., Kato G. Pericarditis and pleuritis associated with human parvovirus B19 infection in a systemic lupus erythematosus patient. Mod. Rheumatol. 2010, 20:617-620.
44. Servant-Delmas A., Lefrère J.J., Morinet F., Pillet S. Advances in human B19 erythrovirus biology. J. Virol. 2010, 84:9658-9665.
45. Servonnet A., Delacour H., Dehan C., Gardet V. Heart fatty-acid binding protein (h-FABP): a new cardiac marker. Ann. Biol. Clin. (Paris) 2006, 64:209-217.
46. Sève P., Ferry T., Koenig M., Cathebras P., Rousset H., Broussolle C. Lupus-like presentation of parvovirus B19 infection. Semin. Arthritis Rheum. 2005, 34:642-648.
47. Tincani A., Rebaioli C.B., Taglietti M., Shoenfeld Y. Heart involvement in systemic lupus erythematosus, anti-phospholipid syndrome and neonatal lupus. Rheumatology (Oxford) 2006, 45(Suppl. 4):iv8-iv13.
48. Tirziu D., Giordano F.J., Simons M. Cell communications in the heart. Circulation 2010, 122:928-937.
49. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheet: procedure and some applications. Proc. Natl. Acad. Sci. U.S.A. 1979, 76:4350-4354.
50. Tsai C.C., Tzang B.S., Chiang S.Y., Hsu G.J., Hsu T.C. Increased expression of matrix metalloproteinase 9 in liver from NZB/W F1 mice received antibody against human parvovirus B19 VP1 unique region protein. J. Biomed. Sci. 2009, 16:14.
51. Tschöpe C., Bock C.T., Kasner M., Noutsias M., Westermann D., Schwimmbeck P.L., Pauschinger M., Poller W.C., Kühl U., Kandolf R., Schultheiss H.P. High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction. Circulation 2005, 111:879-886.
52. Tzang B.S., Lee Y.J., Yang T.P., Tsay G.J., Shi J.Y., Tsai C.C., Hsu T.C. Induction of antiphospholipid antibodies and antiphospholipid syndrome-like autoimmunity in naive mice with antibody against human parvovirus B19 VP1 unique region protein. Clin. Chim. Acta 2007, 382:31-36.
53. Tzang B.S., Tsay G.J., Lee Y.J., Li C., Sun Y.S., Hsu T.C. The association of VP1 unique region protein in acute parvovirus B19 infection and antiphospholipid antibody production. Clin. Chim. Acta 2007, 378:59-65.
54. Tzang B.S., Chiu C.C., Tsai C.C., Lee Y.J., Lu I.J., Shi J.Y., Hsu T.C. Effects of human parvovirus B19 VP1 unique region protein on macrophage responses. J. Biomed. Sci. 2009, 16:13.
55. Urowitz M.B., Bookman A.A., Koehler B.E., Gordon D.A., Smythe H.A., Ogryzlo M.A. The bimodal mortality pattern of systemic lupus erythematosus. Am. J. Med. 1976, 60:221-225.
56. von Landenberg P., Lehmann H.W., Knoll A., Dorsch S., Modrow S. Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection. Arthritis Rheum. 2003, 48:1939-1947.
57. Yokoseki O., Suzuki J., Kitabayashi H., Watanabe N., Wada Y., Aoki M., Morishita R., Kaneda Y., Ogihara T., Futamatsu H., Kobayashi Y., Isobe M. cis Element decoy against nuclear factor-kappaB attenuates development of experimental autoimmune myocarditis in rats. Circ. Res. 2001, 89:899-906.
58. Young N.S., Brown K.E. Parvovirus B19. N. Engl. J. Med. 2004, 350:586-597.